Research programme: antibody-based anti-infectives - InhibRx

Drug Profile

Research programme: antibody-based anti-infectives - InhibRx

Alternative Names: JET-MAB

Latest Information Update: 05 Aug 2016

Price : $50

At a glance

  • Originator Inhibrx
  • Class Antibacterials; Antibodies; Antivirals; Monoclonal antibodies
  • Mechanism of Action Immunostimulants; Surface antigen modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Bacterial infections; Viral infections

Most Recent Events

  • 05 Aug 2016 Preclinical trials in Viral infections in USA (Parenteral)
  • 05 Aug 2016 Preclinical trials in Bacterial infections in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top